Contineum Therapeutics, Inc. (CTNM)
Nasdaq · Healthcare · Biotechnology
$12.72−3.05%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $479M
- 52-week range
- $8.60 – $17.79
- 52-week change
- +15.19%
- EPS (trailing)
- −$1.73
- Analyst rating
- 1.4 Strong buy
- Next earnings
- Oct 29, 2026
Fiscal year to Dec 2025
- Net income
- −$60.0M
- Diluted EPS
- −$2.17
- Free cash flow
- −$55.5M
From the company’s annual report on SEC EDGAR.
About Contineum Therapeutics, Inc.
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
Headquarters: San Diego, United States · 51 employees · contineum-tx.com